A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer
NCT02032277
Completed
This is a 3 arm Phase 3 study to evaluate the safety and efficacy of the addition of veliparib plus carboplatin versus the addition of carboplatin to standard neoadjuvant chemotherapy versus standard neoadjuvant chemotherapy in subjects with early stage TNBC.
Gender:
FEMALE
Ages:
Between 18 years and 99 years
Trial Updated:
01/15/2021
Locations: Oncology Hematology Care, Inc - Blue Ash /ID# 120478, Cincinnati, Ohio +4 locations
Conditions: Triple Negative Breast Cancer
Register for Updates
Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx)
NCT01270724
Completed
This study will look to see how well patients with relapsed or recurrent intracranial germ cell tumors respond to the new combination of chemotherapy (in induction)of Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx) followed by consolidation chemotherapy and autologous stem cell rescue.
Gender:
ALL
Ages:
All
Trial Updated:
01/05/2021
Locations: Nationwide Children's Hospital, Columbus, Ohio +1 locations
Conditions: CNS Germ Cell Tumor
Register for Updates
ASA404 or Placebo in Combination With Paclitaxel and Carboplatin as First-Line Treatment for Stage IIIb/IV Non-Small Cell Lung Cancer
NCT00662597
Terminated
The purpose of this study is to determine if adding ASA404 to standard chemotherapy makes the cancer treatment more effective in patients with advanced lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/16/2020
Locations: Akron City Hospital, Akron, Ohio +4 locations
Conditions: Non-Small Cell Lung Cancer
Register for Updates
Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE)
NCT02436668
Completed
This is a phase 3 study to evaluate the efficacy of ibrutinib in combination with nab-paclitaxel and gemcitabine for the first line treatment of patients with metastatic pancreatic adenocarcinoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/07/2020
Locations: University of Cincinnati Medical Center, Cincinnati, Ohio
Conditions: Metastatic Pancreatic Adenocarcinoma
Register for Updates
A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Untreated, Advanced Non-Small Cell Lung Cancer
NCT01268059
Terminated
The purpose of this study is to evaluate the dose, antitumor activity, safety and pharmacology of MEDI-575 in combination with carboplatin/paclitaxel in subjects with previously untreated, advanced non-small cell lung cancer (NSCLC).
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
12/01/2020
Locations: Research Site, Canton, Ohio
Conditions: Non-small Cell Lung Cancer
Register for Updates
A Survival Study for Women With Advanced Lung Cancer Who Have Not Previously Received Chemotherapy.
NCT00269828
Terminated
This is a randomized, open-label, multinational, phase III study in women with histologically- or cytologically-confirmed advanced NSCLC who are chemotherapy naïve and have PS 2. Study drug will be administered on day 1 of each 21 day cycle
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/23/2020
Locations: University of Cleveland, Cleveland, Ohio +4 locations
Conditions: NSCLC
Register for Updates
Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
NCT02106546
Completed
The purpose of this study is to evaluate the safety and efficacy of the addition of veliparib plus carboplatin and paclitaxel versus the addition of placebo plus carboplatin and paclitaxel in adults with advanced or metastatic squamous non-small cell lung cancer (NSCLC).
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
11/13/2020
Locations: Gabrail Cancer Center Research /ID# 127415, Canton, Ohio
Conditions: Squamous Non-Small Cell Lung Cancer
Register for Updates
Hypofractionated Radiotherapy With Carboplatin and Paclitaxel in Non-Small Cell Lung Cancer
NCT03699033
Withdrawn
Single center, single arm, Phase II study designed to evaluate the feasibility of hypofractionated IMRT to 62.5 Gy in 25 fractions (2.5 Gy/fraction) with 4D PET/CT-based radiation treatment planning and concurrent carboplatin and paclitaxel in Stage IIIA or Stage IIIB NSCLC subjects.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/03/2020
Locations: University of Toledo, Eleanor N. Dana Cancer Center, Toledo, Ohio
Conditions: Non Small Cell Lung Cancer
Register for Updates
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
NCT00030654
Completed
RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Drugs such as luteinizing hormone-releasing hormone agonist, flutamide, and bicalutamide may stop the adrenal glands from producing androgens. Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Combining hormone therapy with chemotherapy may kill more tumor cells. It is not yet known whether chemotherapy given at the same time as hormone therapy is more effective... Read More
Gender:
MALE
Ages:
Between 18 years and 120 years
Trial Updated:
10/21/2020
Locations: Akron General's McDowell Cancer Center, Akron, Ohio +5 locations
Conditions: Prostate Cancer
Register for Updates
Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer
NCT00004054
Completed
RATIONALE: Hormones can stimulate the production of prostate cancer cells. Hormone therapy may fight prostate cancer by reducing the production of androgens. Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether hormone therapy plus radiation therapy is more effective with or without combination chemotherapy for prostate cancer. PURPOSE: Randomized... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
10/19/2020
Locations: Akron General Medical Center, Akron, Ohio +5 locations
Conditions: Prostate Cancer
Register for Updates
Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer
NCT00003930
Completed
RATIONALE: Radiation therapy uses x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy and surgery may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of radiation therapy plus combination chemotherapy in treating patients who have stage II or stage III bladder cancer that can be removed by surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/19/2020
Locations: Akron General Medical Center, Akron, Ohio +10 locations
Conditions: Bladder Cancer
Register for Updates
Chemotherapy and Radiation Therapy in Treating Patients With Stomach Cancer
NCT00003862
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy with radiation therapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of chemotherapy and radiation therapy in treating patients who have stomach cancer.
Gender:
ALL
Ages:
Between 0 years and 120 years
Trial Updated:
10/15/2020
Locations: Ireland Cancer Center, Cleveland, Ohio +2 locations
Conditions: Gastric Cancer
Register for Updates